Wild-type p53 transgenic mice exhibit alterea differentiation of the ureteric bud and possess small kidneys

Genes and Development

Volumn 10, Issue 7, 1996, Pages 836-850

  Godley, Lucy A ^a,b   Kopp, Jeffrey B ^c   Eckhaus, Michael ^d   Paglino, Jennifer J ^c   Owens, Jennie ^d   Varmus, Harold E ^a,b,e  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Kidney development; p53; Transgenic mice; Ureteric bud

Indexed keywords

PROTEIN P53;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; FEMALE; GENE EXPRESSION REGULATION; KIDNEY DEVELOPMENT; KIDNEY SIZE; KIDNEY TUBULE EPITHELIUM; LONG TERMINAL REPEAT; MALE; MESENCHYME; MOUSE; MOUSE MAMMARY TUMOR ONCOVIRUS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; TRANSGENIC MOUSE; URETER;

ANIMALS; ANTIGENS, DIFFERENTIATION; APOPTOSIS; BASE SEQUENCE; BLOOD UREA NITROGEN; FLUORESCENT ANTIBODY TECHNIQUE; GENES, P53; IN SITU HYBRIDIZATION; KIDNEY; KIDNEY FAILURE, CHRONIC; MAMMARY TUMOR VIRUS, MOUSE; MESODERM; MICE; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; MUTATION; ORGAN SIZE; PHENOTYPE; RECOMBINANT FUSION PROTEINS; REPETITIVE SEQUENCES, NUCLEIC ACID; TISSUE DISTRIBUTION; TUMOR SUPPRESSOR PROTEIN P53; URETER;

ANIMALIA; MAMMARY TUMOR ONCOVIRUS; MAMMARY TUMOR VIRUS; MOUSE MAMMARY TUMOR VIRUS; MURINAE; MUS MUSCULUS; ONCOVIRINAE; TUMOR VIRUS;

EID: 0029925957     PISSN: 08909369     EISSN: None     Source Type: Journal    
DOI: 10.1101/gad.10.7.836     Document Type: Article

References (54)

1. Agoff, S.N., J. Hou, D.I.H. Linzer and B. Wu. 1993. Regulation of the human hsp70 promoter by p53. Science 259: 84-87.
2. Bard, J.B.L. 1992. The development of the mouse kidney - Embryogenesis writ small. Curr. Opin. Genet. Devel. 2: 589-595.
3. Beenken, S.W., G. Karsenty, L. Raycroft, and G. Lozano. 1991. An intron binding protein is required for transformation ability of p53. Nucleic Acids Res. 19: 4747-4752.
4. Bergh, J., T. Norberg, S. Sjogren, A. Lindgren, and L Holmberg. 1995. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nature Med. 1: 1029-1034.
5. Brenner, B.M., D.L. Garcia, and S. Anderson. 1988. Glomeruli and blood pressure. Am. J. Hypertens. 1: 335-347.
6. Christofori, G., P. Naik, and D. Hanahan. 1994. A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis. Nature 369: 414-418.
7. Clarke, A R., C.A. Purdie, D.J. Harrison, R.G. Morris, C.C. Bird, M.L. Hooper, and A.H. Wyllie. 1993. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 352: 849-852.
8. Dameron, K.M., O.V. Volpert, M.A. Tainsky, and N. Bouck. 1994. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265: 1582-1584.
9. Donehower, L.A., M. Harvey, B.L. Slagle, M.J. McArthur Jr., C.A. Montgomery, J.S. Butel, and A. Bradley. 1992. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature 356: 215-221.
10. Donehower, L.A., L.A. Godley, C. Marcelo Aldaz, R. Pyle, Y.-P. Shi, D. Pinkel, J. Gray, A. Bradley, D. Medina, and H.E. Varmus. 1995. Deficiency of p53 accelerates mammary tumorigenesis in Wnt-1 transgenic mice and promotes chromosomal instability. Genes &. Dev. 9: 882-895.
11. El-Diery, W.S., T. Tokino, V.E. Velculescu, D.B. Levy, R. Parsons, J.M. Trent, D. Lin, W.E. Mercer, K.W. Kinzler, and B. Vogelstein. 1993. WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825.
12. Gilbert, T., M. Lelievre-Pegoner, and C. Merlet-Benichou. 1991. Long-term effects of mild oligonephronia induced in utero by gentamicin in the rat. Pediatr. Res 30: 450-456.
13. Greenblatt, M.S., W.P. Bennett, M. Hollstein, and C.C. Harris. 1994. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res. 54: 4855-4878.
14. Harper, J.W., G.R. Adami, N. Wei, K. Keyomarsi, and S.J. Elledge. 1993. The p21 CDK-interacting protein Cipl is a potent inhibitor of G1 cyclm-dependent kmases. Cell 75: 805-816.
15. He, C., R.K. Zaulps, D.A. Henderson, G.E. Striker, and L.J. Striker. 1995. Molecular analysis of spontaneous glomerulosclerosis in Os/+ mice, a model with reduced nephron mass. Am. J. Physiol 269: F266-F273.
16. Hogan, B., F. Costantini, and E. Lacy. 1986. In Manipulating the mouse embryo. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
17. Hostetter, T.H., J.L. Olson, H.G. Rennke, M.A. Venkalachalam, and B.M. Brenner. 1981. Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. Am. J. Physiol. 79: F85F93.
18. Howie, A.J., T. Kizaki, M. Beaman, C.M. Morland, R.J. Birtwistle, D. Adu, J. Michael, A.J. Williams, J. Walls, M. Matsuyama, and F. Shimizu. 1989. Different types of segmental sclerosing glomerular lesions in six experimental models of proternuria. J. Pathol. 157: 141-151.
19. Hussussian, CJ., J.P. Struewing, A.M. Goldstein, P.A.T. Higgins, D.S. Ally, M.D. Sheahan, W.H. Clark, M.A. Tucker, and N.C. Dracopoli. 1994. Germline p16 mutations in familial melanoma. Nature Genet. 8: 15-21.
20. Jacks, T., L. Remington, B.O. Williams, E.M. Schmitt, S. Halachmi, R.T. Bronson, and R.A. Weinberg. 1994. Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 4: 1-7.
21. Jayaraman, L. and C. Prives. 1995. Activation of p53 sequence-specific DNA binding by short single strands of DNA requires the p53 C-terminus. Cell 81: 1021-1029.
22. Jones, S.N., A.E. Roe, L.A. Donehower, and A. Bradley. 1995. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 378: 206-208.
23. Kastan, M.B., O. Onyekwere, D. Sidransky, B. Vogelstein, and R.W. Craig. 1991. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51: 6304-6311.
24. Kreidberg, I.A., H. Sariola, J.M. Loring, M. Maeda, J. Pelletier, D. Housman, and R. Jaenisch. 1993. WT-1 is required for early kidney development. Cell 74: 679-691.
25. Kuerbitz, S.J., B.S. Plunkett, W.V. Walsh, and M.B. Kastan. 1992. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. 89: 7491-7495.
26. Lee, S., B. Elenbaas, A. Levine, and J. Griffith. 1995. p53 and its 14kDa C-terminal domain recognize primary DNA damage in the form of insertion/deletion mismatches. Cell 81: 1013-1020.
27. Lowe, S.W., H.E. Ruley, T. Jacks, and D.E. Housman. 1993a. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-967.
28. Lowe, S.W., E.M. Schmitt, S.W Smith, B.A. Osborne, and T. Jacks. 1993b. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362: 847-849.
29. Lowe, S.W., S Bodis, A. McClatchey, L. Remington, H.E. Ruley, D.E. Fisher, D.E. Housman, and T. Jacks. 1994 p53 status and the efficacy of cancer therapy in vivo. Science 266: 807-810.
30. Mack, D.H., J. Vartikar, J.M. Pipas, and L.A. Laimins. 1993. Specific repression of TATA-mediated but not initiator-mediated transcription by wild-type p53. Nature 363: 281-283.
31. MacKay, K., L.J. Striker, C.A. Pinkert, R.L. Brinster, and G.E. Striker. 1987 Glomerulosclerosis and renal cysts in mice transgenic for the early region of SV40. Kidney Int. 32: 827-837.
32. Maheswaran, S., S. Park, A. Bernard, J. Moms, F. Rauscher III, D Hill, and D. Haber. 1993. Physical and functional interaction between WT1 and p53 proteins. Proc. Natl. Acad. Sci 90: 5100-5104.
33. Maheswaran, S., C. Englert, P. Bennett, G. Heinrich, and D.A. Haber. 1995. The WT1 gene product stabilizes p53 and inhibits p53-mediated apoptosis. Genes &. Dev. 9: 2143-2156.
34. McGraw, M., S. Poucell, J. Sweet, and R. Baumal. 1984. The significance of focal segmental glomerulosclerosis in oligomeganephronia. Int. J. Pediatr. Nephrol. 5: 67-72.
35. Michalovitz, O., O. Halevy, and M. Oren. 1990. Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell 62: 671-680.
36. Milner, J. and E.A. Medcalf. 1990. Temperature-dependent switching between "wild-type" and "mutant" forms of p53-Val135. J. Mol Biol. 216: 481-484.
37. Montes de Oca Luna, R., D.S. Wagner, and G. Lozano. 1995. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378: 203-206.
38. Morham, S.G., R. Langenbach, C.D Loftin, H.F. Tiano, N. Vouloumanos, J.C. Jennette, J.F. Mahler, K.D. Kluckman, A. Ledford, C A. Lee, and O. Smithies. 1995. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 83: 473-482.
39. Nakamura, T., J.G. Pichel, L. Williams-Simons, and H. Westphal. 1995. An apoptotic defect in lens differentiation caused by human p53 is rescued by a mutant allele. Proc. Natl. Acad. Sci. 92: 6142-6146.
40. Pachnis, V., B. Mankoo, and F. Costantim. 1993. Expression of c-ret proto-oncogene during mouse embryogenesis. Development 119: 1005-1017.
41. Pan, H. and A.E. Griep. 1995. Temporally distinct patterns of p53-dependent and p53-independent apoptosis during mouse lens development. Genes &. Dev. 9: 2157-2169.
42. Pritchard-Jones, K., S. Fleming, D. Davidson, W Bickmore, D. Porteous, C. Gosden, J. Bard, A. Buckler, J. Pelletier, D. Housman, V. van Heyningen, and N. Hastie. 1990. The candidate Wilms' tumour gene is involved in genitourinary development. Nature 346: 194-197.
43. Purdie, C.A., D.J. Harrison, A. Peter, L. Dobbie, S. White, S.E.M. Howie, D.M. Salter, C.C. Bird, A.H. Wyllie, M.L. Hooper, and A.R. Clarke. 1994. Tumour incidence, spectrum, and ploidy in mice with a large deletion in the p53 gene. Oncogene 9: 603-609.
44. Reed, M., B. Woelker, P. Wang, Y. Wang, M.E. Anderson, and P. Tegtmeyer. 1995. The C-terminal domain of p53 recognizes DNA damaged by ionizing radiation. Proc. Natl Acad. Sci 92: 9455-9459.
45. Royer, P., R. Habib, H. Mathieu, and V. Courtecuisse. 1962. L'hypoplasie rénal bilatérale congénitale avec réduction du nombe et hypertrophie des néphrons chez l'enfant. Ann. Pediatr. 9: 133-146.
46. Sabolic, I., T Katsura, J.-M. Verbavatz, and D. Brown. 1995. The AQP2 water channel: Effect of vasopressin treatment, microtubule disruption, and distribution in neonatal rats. J. Membrane Biol 143: 165-175.
47. Sah, V.P., L.D. Attardi, G.J. Mulligan, B.O. Williams, R.T. Bronson, and T. Jacks. 1995 A subset of p53-deficient embryos exhibit exencephaly. Nature Genet 10: 175-180.
48. Schmid, P., A. Lorenz, H. Hameister, and M. Montenarh. 1991. Expression of p53 during mouse embryogenesis. Development 113: 857-865.
49. Schuchardt, A., V. D'Agati, L. Larsson-Blomberg, F Costantini, and V. Pachnis. 1994. Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret. Nature 367: 380-383.
50. Seto, E., A. Usheva, G.P. Zambetti, J. Momand, N. Honkoshi, R. Weinmann, A.J. Levine, and T. Shenk. 1992. Wild-type p53 binds to the TATA-binding protein and represses transcription. Proc. Natl. Acad. Sci 89: 12028-12032.
51. Thut, C.J., J.-L. Chen, R. Klemm, and R. Tjian. 1995. p53 transcriptional activation mediated by coactivators TAFII40 and TAFII60. Science 267: 100-104.
52. Tsukamoto, A.S., R. Grosschedl, R.C. Guman, T. Parslow, and H.E. Varmus. 1988. Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice. Cell 55: 619-625.
53. Weibel, E.R. 1979. Stereologic methods. Academic Press, London, UK.
54. Yonish-Rouach, E., D. Resnitzky, J. Lotem, L. Sachs, A. Kimchi, and M. Oren. 1991. Wild-type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin-6 Nature 352: 345-347.